Third Quarter

Third Quarter

American Airlines

American Airlines

Marks Down Third Quarter Guidance

Marks Down Third Quarter Guidance

American Airlines Group Inc

American Airlines Group Inc

weigh

weigh

in the third quarter

in the third quarter

American Airlines Group Inc

American Airlines Group Inc

weigh on its earnings

weigh on its earnings

in the quarter

in the quarter

American Airlines Group Inc

American Airlines Group Inc

compared with earlier expectations

compared with earlier expectations

up to 1 %

up to 1 %

unit revenue will expand

unit revenue will expand

year-over-year

year-over-year

American Airlines Group Inc

American Airlines Group Inc

2.5 %

2.5 %

rise

rise

American

American

costs

costs

in the quarter

in the quarter

American

American

weigh on its pretax margin

weigh on its pretax margin

in the quarter

in the quarter

up to 10.5 %

up to 10.5 %

up to 12 %

up to 12 %

its

its

pretax margin

pretax margin

third-quarter

third-quarter

Most of American 's major rivals

Most of American 's major rivals

reined in their third-quarter guidance

reined in their third-quarter guidance

Most of American 's major rivals

Most of American 's major rivals

deteriorating revenue

deteriorating revenue

Most of American 's major rivals

Most of American 's major rivals

a deteriorating revenue environment

a deteriorating revenue environment

environment

environment

third-quarter

third-quarter

Most of American 's major rivals

Most of American 's major rivals

pricier fuel

pricier fuel

last month

last month

in Texas

in Texas

Southwest Airlines Co.

Southwest Airlines Co.

United Continental Holdings Inc.

United Continental Holdings Inc.

Spirit Airlines Inc.

Spirit Airlines Inc.

revenue hits

revenue hits

last month

last month

in Texas

in Texas

disruptions

disruptions

Miami

Miami

hub in Miami

hub in Miami

American

American

runs a hub

runs a hub

since Sept. 5

since Sept. 5

about 5,000 flights

about 5,000 flights

American

American

canceled

canceled

Tuesday

Tuesday

Orlando , a base for Southwest

Orlando , a base for Southwest

reopened

reopened

Wednesday

Wednesday

flights

flights

American

American

restart

restart

in the coming days

in the coming days

Carriers

Carriers

their daily flights

their daily flights

ramp up

ramp up

flights

flights

canceled

canceled

third-quarter

third-quarter

$ 139 million

$ 139 million

harm

harm

$ 35 million

$ 35 million

American

American

price tag

price tag

Tuesday

Tuesday

American

American

to $ 46.29

to $ 46.29

nearly 1 %

nearly 1 %

shares were up

shares were up

flights canceled

American Airlines Group Inc

American Airlines Group Inc

flights canceled

Most of American 's major rivals

Most of American 's major rivals

rebuilding its diminished schedule

American

American

rebuilding its diminished schedule

Some flights resumed

JetBlue Airways Corp

JetBlue Airways Corp

Spirit

Spirit

Some flights resumed

airlines

airlines

trouble finding lodging

airlines

airlines

trouble finding lodging

declined to comment

American

American

declined to comment

include a preliminary storm tally

American

American

include a preliminary storm tally

American Airlines Marks Down Third Quarter Guidance
American Airlines Group Inc. said flights canceled due to Hurricane Irma will weigh on its earnings in the third quarter .
The nation 's top airline by traffic said Tuesday that its unit revenue will expand up to 1 % in the quarter compared with earlier expectations for as much as a 2.5 % rise year-over-year .
Unit revenue is the amount an airline earns for each seat flown a mile .
American also said higher fuel costs would weigh on its pretax margin in the quarter .
The Fort Worth , Texas-based carrier said its pretax margin will be up to 10.5 % in the quarter , compared with an earlier forecast of up to 12 % .
Most of American 's major rivals already have reined in their third-quarter guidance , citing a deteriorating revenue environment and pricier fuel .
United Continental Holdings Inc. , Southwest Airlines Co. and Spirit Airlines Inc. also disclosed revenue hits from the disruptions caused by Hurricane Harvey in Texas last month .
American , which runs a hub in Miami , is rebuilding its diminished schedule in the wake of Irma , which barreled up the Florida peninsula last weekend after wreaking havoc in the northern Caribbean .
The company said it has canceled about 5,000 flights since Sept. 5 .
Some flights resumed Tuesday in Miami and Fort Lauderdale -- the latter city is a big base for JetBlue Airways Corp. and Spirit .
Orlando , a base for Southwest , reopened on a limited basis Tuesday , as did several other airports including West Palm Beach , Tallahassee , Jacksonville and Gainesville .
American said it plans to restart flights to Tampa and Sarasota on Wednesday .
Carriers are expected to ramp up their daily flights in the coming days , but many customers whose flights were canceled still need to be transported .
Moreover , airlines are contending with hotels full of stranded travelers and are having trouble finding lodging for their crew members .
Cowen & Co. on Tuesday estimated that Irma inflicted $ 139 million of third-quarter harm on the six largest U.S. carriers in the region , led by American , with a $ 35 million price tag .
American declined to comment , and its Tuesday disclosure did n't include a preliminary storm tally .
American shares were up nearly 1 % Tuesday to $ 46.29 .

American Airlines Marks Down Third Quarter Guidance American Airlines Group Inc . said flights canceled due to Hurricane Irma will weigh on its earnings in the third quarter . The nation ' s top airline by traffic said Tuesday that its unit revenue will expand up to 1 % in the quarter compared with earlier expectations for as much as a 2.5 % rise year-over-year . Unit revenue is the amount an airline earns for each seat flown a mile . American also said higher fuel costs would weigh on its pretax margin in the quarter . The Fort Worth , Texas-based carrier said its pretax margin will be up to 10.5 % in the quarter , compared with an earlier forecast of up to 12 % . Most of American ' s major rivals already have reined in their third-quarter guidance , citing a deteriorating revenue environment and pricier fuel . United Continental Holdings Inc . , Southwest Airlines Co . and Spirit Airlines Inc . also disclosed revenue hits from the disruptions caused by Hurricane Harvey in Texas last month . American , which runs a hub in Miami , is rebuilding its diminished schedule in the wake of Irma , which barreled up the Florida peninsula last weekend after wreaking havoc in the northern Caribbean . The company said it has canceled about 5,000 flights since Sept . 5 . Some flights resumed Tuesday in Miami and Fort Lauderdale - - the latter city is a big base for JetBlue Airways Corp . and Spirit . Orlando , a base for Southwest , reopened on a limited basis Tuesday , as did several other airports including West Palm Beach , Tallahassee , Jacksonville and Gainesville . American said it plans to restart flights to Tampa and Sarasota on Wednesday . Carriers are expected to ramp up their daily flights in the coming days , but many customers whose flights were canceled still need to be transported . Moreover , airlines are contending with hotels full of stranded travelers and are having trouble finding lodging for their crew members . Cowen & Co . on Tuesday estimated that Irma inflicted $ 139 million of third-quarter harm on the six largest U.S . carriers in the region , led by American , with a $ 35 million price tag . American declined to comment , and its Tuesday disclosure did n't include a preliminary storm tally . American shares were up nearly 1 % Tuesday to $ 46.29 .


experts

experts

the six Dow stocks

the six Dow stocks

upside

upside

this year

this year

Stocks on Wall Street

Stocks on Wall Street

surged higher

surged higher

in the past 12 months

in the past 12 months

double-digit

double-digit

gains

gains

many stocks

many stocks

analysts

analysts

overpriced

overpriced

this year

this year

in the larger markets

in the larger markets

movement in the larger markets

movement in the larger markets

nearly 7 percent year-to-date

nearly 7 percent year-to-date

The Dow

The Dow

surged

surged

in the past year

in the past year

The Dow

The Dow

a more than 18 percent

a more than 18 percent

gain

gain

tech giants Apple Inc

tech giants Apple Inc

industrial manufacturer Caterpillar Inc

industrial manufacturer Caterpillar Inc

Intel Corp

Intel Corp

energy giant Chevron Corp

energy giant Chevron Corp

Two experts

Two experts

retailer Wal-Mart Stores Corp

retailer Wal-Mart Stores Corp

six of the Dow 30 component stocks

six of the Dow 30 component stocks

suggested

suggested

this year so far

this year so far

in the spring

in the spring

Two of the others , Intel and JPMorgan

Two of the others , Intel and JPMorgan

gains

gains

Two of the others , Intel and JPMorgan

Two of the others , Intel and JPMorgan

giving back some ground .

giving back some ground .

this year

this year

Chevron

Chevron

stocks that has been steadily down

stocks that has been steadily down

to the current bull market

to the current bull market

threats

threats

threats

threats

throughout the remainder of the year

throughout the remainder of the year

U.S. stock markets

U.S. stock markets

climb

climb

in the 9 percent to 13 percent range

in the 9 percent to 13 percent range

return

return

upside

upside

Russell

Russell

Chevron , Caterpillar and Apple

Chevron , Caterpillar and Apple

picks

picks

Russell

Russell

many stocks

many stocks

overbought

overbought

Russell

Russell

the market

the market

climb

climb

priced in

priced in

the market

the market

correction

correction

today

today

the stock market

the stock market

risk

risk

currently

currently

Watson

Watson

options

options

year-to-date

year-to-date

The broader market index of the S&P 500

The broader market index of the S&P 500

8 percent year-to-date

8 percent year-to-date

is nearly 8 percent

is nearly 8 percent

in the past year

in the past year

The broader market index of the S&P 500

The broader market index of the S&P 500

more than 15 percent

more than 15 percent

gained

gained

The tech-heavy Nasdaq

The tech-heavy Nasdaq

gained

gained

Chevron

Chevron

4 %

4 %

dividend

dividend

Chevron

Chevron

earnings turnaround

earnings turnaround

Caterpillar

Caterpillar

stock price is fairly valued

stock price is fairly valued

Caterpillar

Caterpillar

3 %

3 %

dividend

dividend

Apple

Apple

launch

launch

Apple

Apple

invested

invested

their new 5 billion dollar headquarters

their new 5 billion dollar headquarters

Apple

Apple

headquarters

headquarters

Apple

Apple

product development

product development

Apple

Apple

1.5 %

1.5 %

dividend

dividend

in the coming years

in the coming years

Apple

Apple

increase

increase

still some good investments

in the larger markets

in the larger markets

still some good investments

this year looks good

in the larger markets

in the larger markets

this year looks good

good choices for investing

Two experts

Two experts

six of the Dow 30 component stocks

six of the Dow 30 component stocks

good choices for investing

have been up and down

Two of the others , Intel and JPMorgan

Two of the others , Intel and JPMorgan

have been up and down

oil prices creeping back up of late

Chevron

Chevron

oil prices creeping back up of late

have potential .

Chevron

Chevron

have potential .

to the current bull market

to the current bull market

take a breather

U.S. stock markets

U.S. stock markets

take a breather

Russell

Russell

Russell

Russell

expensive

many stocks

many stocks

expensive

dangerously high levels

many stocks

many stocks

the market

the market

dangerously high levels

prudent

prudent

recommending

conservative allocation to stocks

conservative allocation to stocks

recommending

concerns

expensive stock market valuations

expensive stock market valuations

concerns

started to decline from higher levels

investor sentiment

investor sentiment

started to decline from higher levels

concerns

many stocks

many stocks

concerns

stocks have to decline

stocks

stocks

stocks have to decline

stocks as vulnerable to a decline

stocks

stocks

stocks as vulnerable to a decline

a great value play

Chevron

Chevron

a great value play

get paid

Chevron

Chevron

get paid

plenty of upside in the stocks ' price

Chevron

Chevron

plenty of upside in the stocks ' price

benefit greatly

CAT

CAT

benefit greatly

orders for equipment begin to flood in

CAT

CAT

orders for equipment begin to flood in

obvious choice

Apple

Apple

obvious choice

Apple

Apple

their new 5 billion dollar headquarters

their new 5 billion dollar headquarters

Here are the six Dow stocks experts say have the most upside
Stocks on Wall Street have surged higher this year , with double-digit gains in the past 12 months for the Nasdaq , S&P 500 and the Dow Jones Industrial Average .
While analysts caution that many stocks may be overpriced , there are still some good investments out there and this year looks good for more upward movement in the larger markets .
The Dow has surged nearly 7 percent year-to-date , with a more than 18 percent gain in the past year .
Two experts we talked to suggested six of the Dow 30 component stocks as good choices for investing now , if someone wanted to eye the big stocks .
Among those are tech giants Apple Inc. and Intel Corp. , along with energy giant Chevron Corp. , industrial manufacturer Caterpillar Inc. , banking and finance titan JPMorgan Chase , as well as retailer Wal-Mart Stores Corp. .
Of those six stocks , Walmart , Apple and Caterpillar have already posted big gains this year so far .
Two of the others , Intel and JPMorgan , both have been up and down after initially posted gains in the spring before giving back some ground .
Chevron is the one of those stocks that has been steadily down this year , but with oil prices creeping back up of late it appears to have potential .
`` The biggest threats to the current bull market are geopolitical North Korea , political scandals , etc. and a failure to revise and reduce tax rates for U.S. businesses , '' said Rob Russell , president of Russell Total Wealth Management in Fairborn .
`` Barring these threats , the U.S. stock markets will likely take a breather during the summer and then climb higher throughout the remainder of the year , with a yearly return in the 9 percent to 13 percent range . ''
Russell said the broader market of the S&P 600 , which is comprised of small-cap U.S. based companies , likely has the most upside `` due to the heavy emphasis from D.C. on small businesses , tax friendly policies , and softer regulation . ''
But his Dow 30 picks would be Chevron , Caterpillar and Apple .
Russell added as a disclosure that he , his family , and his clients owned positions in CVX and AAPL at the time of this writing .
`` Undoubtedly , many stocks are already overbought and expensive , but even at these dangerously high levels it is possible for the market to continue to climb higher , '' Russell said .
`` Eventually , reality will be priced in and the market will experience a correction , which is why it 's prudent to begin diversifying your portfolio outside of common stocks and bonds by including Private Equity and Opportunistic Real Estate . ''
Matt Watson , portfolio manager for James Investment Research in Greene County , said that his firm is currently recommending a conservative allocation to stocks .
`` We have some concerns regarding expensive stock market valuations , '' Watson said .
`` Additionally , investor sentiment towards stocks has started to decline from higher levels reached earlier this year .
While these concerns do not mean that stocks have to decline , we view stocks as vulnerable to a decline due to the higher risk levels we perceive in the stock market today . ''
As for which Dow stocks he believes would be options for investors , Watson said `` Intel , Wal-Mart , and JP Morgan are a few of the Dow stocks that we currently own for some of our clients . ''
The broader market index of the S&P 500 is nearly 8 percent year-to-date and has gained more than 15 percent in the past year .
The tech-heavy Nasdaq has gained the most of the big three indices , with the Nasdaq posting a 15 percent gain year-to-date and is up more than 25 percent in the past year .
Russell added some insight about his three picks :
- Chevron -- with a 4 % dividend and a recent earnings turnaround this could be a great value play .
In essence , you get paid to wait for oil prices to recover and plenty of upside in the stocks ' price .
- Caterpillar -- you ca n't repair America 's infrastructure without heavy construction equipment and that 's where CAT comes in .
Their other product lines of gas and diesel engines , mining equipment , and locomotives should benefit greatly by Federal , State , and Private industry infrastructure and construction spending in the coming years .
Although the stock price is fairly valued you get a nice 3 % dividend to be patient while orders for equipment begin to flood in .
- Apple -- the obvious choice of the 30 Dow stocks due to a big upcoming product launch and hoards of cash scheduled to be invested .
The move to their new 5 billion dollar headquarters will help to spur new and exciting product development and collaboration among their 12,000 employees .
Although Apple 's dividend is relatively low at 1.5 % currently , it 's likely to increase in the coming years .

Here are the six Dow stocks experts say have the most upside Stocks on Wall Street have surged higher this year , with double-digit gains in the past 12 months for the Nasdaq , S & P 500 and the Dow Jones Industrial Average . While analysts caution that many stocks may be overpriced , there are still some good investments out there and this year looks good for more upward movement in the larger markets . The Dow has surged nearly 7 percent year-to-date , with a more than 18 percent gain in the past year . Two experts we talked to suggested six of the Dow 30 component stocks as good choices for investing now , if someone wanted to eye the big stocks . Among those are tech giants Apple Inc . and Intel Corp . , along with energy giant Chevron Corp . , industrial manufacturer Caterpillar Inc . , banking and finance titan JPMorgan Chase , as well as retailer Wal-Mart Stores Corp . . Of those six stocks , Walmart , Apple and Caterpillar have already posted big gains this year so far . Two of the others , Intel and JPMorgan , both have been up and down after initially posted gains in the spring before giving back some ground . Chevron is the one of those stocks that has been steadily down this year , but with oil prices creeping back up of late it appears to have potential . ` ` The biggest threats to the current bull market are geopolitical North Korea , political scandals , etc . and a failure to revise and reduce tax rates for U.S . businesses , ' ' said Rob Russell , president of Russell Total Wealth Management in Fairborn . ` ` Barring these threats , the U.S . stock markets will likely take a breather during the summer and then climb higher throughout the remainder of the year , with a yearly return in the 9 percent to 13 percent range . ' ' Russell said the broader market of the S & P 600 , which is comprised of small-cap U.S . based companies , likely has the most upside ` ` due to the heavy emphasis from D.C . on small businesses , tax friendly policies , and softer regulation . ' ' But his Dow 30 picks would be Chevron , Caterpillar and Apple . Russell added as a disclosure that he , his family , and his clients owned positions in CVX and AAPL at the time of this writing . ` ` Undoubtedly , many stocks are already overbought and expensive , but even at these dangerously high levels it is possible for the market to continue to climb higher , ' ' Russell said . ` ` Eventually , reality will be priced in and the market will experience a correction , which is why it ' s prudent to begin diversifying your portfolio outside of common stocks and bonds by including Private Equity and Opportunistic Real Estate . ' ' Matt Watson , portfolio manager for James Investment Research in Greene County , said that his firm is currently recommending a conservative allocation to stocks . ` ` We have some concerns regarding expensive stock market valuations , ' ' Watson said . ` ` Additionally , investor sentiment towards stocks has started to decline from higher levels reached earlier this year . While these concerns do not mean that stocks have to decline , we view stocks as vulnerable to a decline due to the higher risk levels we perceive in the stock market today . ' ' As for which Dow stocks he believes would be options for investors , Watson said ` ` Intel , Wal-Mart , and JP Morgan are a few of the Dow stocks that we currently own for some of our clients . ' ' The broader market index of the S & P 500 is nearly 8 percent year-to-date and has gained more than 15 percent in the past year . The tech-heavy Nasdaq has gained the most of the big three indices , with the Nasdaq posting a 15 percent gain year-to-date and is up more than 25 percent in the past year . Russell added some insight about his three picks : - Chevron - - with a 4 % dividend and a recent earnings turnaround this could be a great value play . In essence , you get paid to wait for oil prices to recover and plenty of upside in the stocks ' price . - Caterpillar - - you ca n't repair America ' s infrastructure without heavy construction equipment and that ' s where CAT comes in . Their other product lines of gas and diesel engines , mining equipment , and locomotives should benefit greatly by Federal , State , and Private industry infrastructure and construction spending in the coming years . Although the stock price is fairly valued you get a nice 3 % dividend to be patient while orders for equipment begin to flood in . - Apple - - the obvious choice of the 30 Dow stocks due to a big upcoming product launch and hoards of cash scheduled to be invested . The move to their new 5 billion dollar headquarters will help to spur new and exciting product development and collaboration among their 12,000 employees . Although Apple ' s dividend is relatively low at 1.5 % currently , it ' s likely to increase in the coming years .


Digestive Disease Week

Digestive Disease Week

Gastroenterology

Gastroenterology

AbbVie

AbbVie

Hepatology

Hepatology

Leadership

Leadership

this year

this year

AbbVie

AbbVie

innovative new approaches

innovative new approaches

developing

developing

after 16 weeks of treatment

after 16 weeks of treatment

upadacitinib

upadacitinib

study

study

one year

one year

AbbVie

AbbVie

risankizumab

risankizumab

study

study

Boehringer Ingelheim

Boehringer Ingelheim

Risankizumab

Risankizumab

AbbVie

AbbVie

collaboration

collaboration

globally

globally

AbbVie

AbbVie

leading

leading

HUMIRA

HUMIRA

AbbVie

AbbVie

evaluation

evaluation

AbbVie

AbbVie

HUMIRA

HUMIRA

evaluation

evaluation

AbbVie

AbbVie

HUMIRA

HUMIRA

evaluation

evaluation

AbbVie

AbbVie

analysis

analysis

accepted

accepted

in 8 weeks

in 8 weeks

G/P

G/P

evaluated

evaluated

AbbVie

AbbVie

G/P

G/P

studying

studying

AbbVie

AbbVie

Enanta Pharmaceuticals ENTA

Enanta Pharmaceuticals ENTA

collaboration

collaboration

Late-Breaking Studies

AbbVie

AbbVie

Late-Breaking Studies

promising investigational agents

AbbVie

AbbVie

promising investigational agents

deep knowledge and expertise

AbbVie

AbbVie

deep knowledge and expertise

to strive for improved patient outcomes

AbbVie

AbbVie

to strive for improved patient outcomes

late-breaking studies

AbbVie

AbbVie

late-breaking studies

targets an inflammatory pathway

upadacitinib

upadacitinib

targets an inflammatory pathway

important role

upadacitinib

upadacitinib

important role

a key signaling agent

AbbVie

AbbVie

a key signaling agent

AbbVie

AbbVie

supported by more than

AbbVie

AbbVie

supported by more than

in as little as

AbbVie

AbbVie

in as little as

priority review designation

AbbVie

AbbVie

priority review designation

safety and efficacy

AbbVie

AbbVie

safety and efficacy

AbbVie

AbbVie

unmet need

AbbVie

AbbVie

unmet need

cure

G/P

G/P

AbbVie

AbbVie

cure

AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week
AbbVie ( ABBV ) , a global biopharmaceutical company , today announced that data from 20 abstracts in gastroenterology and hepatology programs will be presented at Digestive Disease Week ® DDW 2017 , May 6 -- 9 , in Chicago .
`` AbbVie 's research presented at DDW this year represents our commitment to developing innovative new approaches , both through continued HUMIRA research and exploring three promising investigational agents across gastroenterology and hepatology , '' said Shao-Lee Lin , M.D. , Ph.D. , Vice President , Therapeutic Areas and International Development , AbbVie .
`` Building on our deep knowledge and expertise in these areas , we are proud to strive for improved patient outcomes . ''
AbbVie will present late-breaking studies on two investigational treatments for moderately to severely active Crohn 's disease during the Clinical Science : Late-Breaking Abstract Plenary Session on Tuesday , May 9 .
The late-breaking research includes a Phase 2 study that evaluates the safety and efficacy of multiple dosing regimens of upadacitinib as induction therapy in patients with moderately to severely active Crohn 's disease after 16 weeks of treatment .
The majority of these patients had failed two or more biologics .
Upadacitinib is an investigational oral JAK1-selective inhibitor , which targets an inflammatory pathway that plays an important role in Crohn 's disease and several other chronic immune-mediated conditions .
AbbVie will also present a Phase 2 , open-label maintenance therapy study that evaluates clinical and endoscopic remission , and clinical and endoscopic response of risankizumab at one year in patients with moderately to severely active Crohn 's disease .
Risankizumab selectively blocks interleukin-23 IL-23 , a key signaling agent that has been linked to a number of chronic immune-mediated diseases .
Risankizumab is an investigational treatment that is part of a collaboration between Boehringer Ingelheim and AbbVie , with AbbVie leading future development and commercialization of risankizumab globally .
Additionally , AbbVie will present new HUMIRA analyses , including an evaluation of patients with ulcerative colitis treated in a clinical practice setting , an evaluation of the long-term safety of HUMIRA in patients with moderately to severely active Crohn 's disease , and an evaluation of the efficacy of HUMIRA in anti-tumor necrosis factor-naïve pediatric patients with Crohn 's disease .
HUMIRA is one of the most comprehensively studied biologics available for immune-mediated diseases and is supported by more than 14 years of clinical trial experience in inflammatory bowel disease Crohn 's disease and ulcerative colitis .
Data from AbbVie 's hepatitis C virus HCV clinical development program will be presented in six presentations throughout the meeting .
These studies provide primary and integrated analysis of treatment with its investigational , once-daily , ribavirin-free , pan-genotypic regimen of glecaprevir/pibrentasvir G/P in patients across all major genotypes GT1-6 .
The results investigate the potential of G/P in patients with specific treatment challenges and explore a virologic cure * in as little as 8 weeks of treatment for HCV patients without cirrhosis and those new to treatment , who make up the majority of HCV patients .
The new drug application NDA for G/P has been accepted by the U.S. Food and Drug Administration ( FDA ) with priority review designation and is currently under review .
G/P is an investigational regimen and its safety and efficacy has not been established .
About AbbVie 's HCV Clinical Development Program
AbbVie 's glecaprevir/pibrentasvir G/P clinical development program was designed to investigate a faster path to virologic cure * for all major HCV genotypes GT1-6 and with the goal of addressing treatment areas of continued unmet need .
G/P is an investigational , pan-genotypic regimen being evaluated as a potential cure in 8 weeks for HCV patients without cirrhosis and who are new to treatment with direct-acting antivirals DAA ** , who make up the majority of HCV patients .
AbbVie is also studying G/P in patients with specific treatment challenges , such as genotype 3 , patients who were not cured with previous DAA treatment and those with CKD , including patients on dialysis .
G/P is a once-daily regimen that combines two distinct antiviral agents .
G/P is a fixed-dose combination of glecaprevir 300 mg , an NS3/4A protease inhibitor , and pibrentasvir 120 mg , an NS5A inhibitor , dosed once-daily as three oral tablets .
Glecaprevir GLE was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals ENTA for HCV protease inhibitors and regimens that include protease inhibitors .

AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week AbbVie ( ABBV ) , a global biopharmaceutical company , today announced that data from 20 abstracts in gastroenterology and hepatology programs will be presented at Digestive Disease Week ® DDW 2017 , May 6 - - 9 , in Chicago . ` ` AbbVie ' s research presented at DDW this year represents our commitment to developing innovative new approaches , both through continued HUMIRA research and exploring three promising investigational agents across gastroenterology and hepatology , ' ' said Shao-Lee Lin , M.D . , Ph.D . , Vice President , Therapeutic Areas and International Development , AbbVie . ` ` Building on our deep knowledge and expertise in these areas , we are proud to strive for improved patient outcomes . ' ' AbbVie will present late-breaking studies on two investigational treatments for moderately to severely active Crohn ' s disease during the Clinical Science : Late-Breaking Abstract Plenary Session on Tuesday , May 9 . The late-breaking research includes a Phase 2 study that evaluates the safety and efficacy of multiple dosing regimens of upadacitinib as induction therapy in patients with moderately to severely active Crohn ' s disease after 16 weeks of treatment . The majority of these patients had failed two or more biologics . Upadacitinib is an investigational oral JAK1 - selective inhibitor , which targets an inflammatory pathway that plays an important role in Crohn ' s disease and several other chronic immune-mediated conditions . AbbVie will also present a Phase 2 , open-label maintenance therapy study that evaluates clinical and endoscopic remission , and clinical and endoscopic response of risankizumab at one year in patients with moderately to severely active Crohn ' s disease . Risankizumab selectively blocks interleukin - 23 IL - 23 , a key signaling agent that has been linked to a number of chronic immune-mediated diseases . Risankizumab is an investigational treatment that is part of a collaboration between Boehringer Ingelheim and AbbVie , with AbbVie leading future development and commercialization of risankizumab globally . Additionally , AbbVie will present new HUMIRA analyses , including an evaluation of patients with ulcerative colitis treated in a clinical practice setting , an evaluation of the long-term safety of HUMIRA in patients with moderately to severely active Crohn ' s disease , and an evaluation of the efficacy of HUMIRA in anti-tumor necrosis factor-naïve pediatric patients with Crohn ' s disease . HUMIRA is one of the most comprehensively studied biologics available for immune-mediated diseases and is supported by more than 14 years of clinical trial experience in inflammatory bowel disease Crohn ' s disease and ulcerative colitis . Data from AbbVie ' s hepatitis C virus HCV clinical development program will be presented in six presentations throughout the meeting . These studies provide primary and integrated analysis of treatment with its investigational , once-daily , ribavirin-free , pan-genotypic regimen of glecaprevir / pibrentasvir G / P in patients across all major genotypes GT1 - 6 . The results investigate the potential of G / P in patients with specific treatment challenges and explore a virologic cure * in as little as 8 weeks of treatment for HCV patients without cirrhosis and those new to treatment , who make up the majority of HCV patients . The new drug application NDA for G / P has been accepted by the U.S . Food and Drug Administration ( FDA ) with priority review designation and is currently under review . G / P is an investigational regimen and its safety and efficacy has not been established . About AbbVie ' s HCV Clinical Development Program AbbVie ' s glecaprevir / pibrentasvir G / P clinical development program was designed to investigate a faster path to virologic cure * for all major HCV genotypes GT1 - 6 and with the goal of addressing treatment areas of continued unmet need . G / P is an investigational , pan-genotypic regimen being evaluated as a potential cure in 8 weeks for HCV patients without cirrhosis and who are new to treatment with direct-acting antivirals DAA * * , who make up the majority of HCV patients . AbbVie is also studying G / P in patients with specific treatment challenges , such as genotype 3 , patients who were not cured with previous DAA treatment and those with CKD , including patients on dialysis . G / P is a once-daily regimen that combines two distinct antiviral agents . G / P is a fixed-dose combination of glecaprevir 300 mg , an NS3 / 4A protease inhibitor , and pibrentasvir 120 mg , an NS5A inhibitor , dosed once-daily as three oral tablets . Glecaprevir GLE was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals ENTA for HCV protease inhibitors and regimens that include protease inhibitors .


Performance Desktop GPU Space

Performance Desktop GPU Space

AMD

AMD

Re-enters

Re-enters

AMD

AMD

desktop CPUs

desktop CPUs

AMD

AMD

unit market share

unit market share

boost in unit market share

boost in unit market share

AMD

AMD

launched

launched

NVIDIA

NVIDIA

AMD

AMD

GPU

GPU

competitive

competitive

NVIDIA

NVIDIA

AMD

AMD

competitive

competitive

NVIDIA

NVIDIA

AMD

AMD

compete with

compete with

March this year

March this year

GTX 1080 Ti

GTX 1080 Ti

NVIDIA

NVIDIA

announced

announced

AMD

AMD

gain credibility and profitability

gain credibility and profitability

AMD

AMD

praise

praise

NVIDIA

NVIDIA

AMD

AMD

competitive

competitive

AMD

AMD

series of bundles

series of bundles

releasing

releasing

RX Vega 56

RX Vega 56

AMD

AMD

additional sales

additional sales

AMD

AMD

positive reviews

positive reviews

early 2018

early 2018

NVIDIA

NVIDIA

introduce

introduce

$ 399 and $ 499 price points

$ 399 and $ 499 price points

AMD

AMD

NVIDIA

NVIDIA

both participate

both participate

close attention

AMD

AMD

close attention

expectations have been met

AMD

AMD

expectations have been met

wait and see

AMD

AMD

wait and see

bring more competition

AMD

AMD

bring more competition

margin dollars

AMD

AMD

margin dollars

increase revenues and margin dollars

AMD

AMD

increase revenues and margin dollars

vast array of performance numbers

AMD

AMD

vast array of performance numbers

very fast .

AMD

AMD

very fast .

launch a new high-end GPU

AMD

AMD

launch a new high-end GPU

compete at higher price points

AMD

AMD

compete at higher price points

competitive with them on price

AMD

AMD

competitive with them on price

competitive with them on price

NVIDIA

NVIDIA

competitive with them on price

superb Instinct performance numbers

AMD

AMD

superb Instinct performance numbers

absolute performance claims

AMD

AMD

absolute performance claims

overall improvements

AMD

AMD

overall improvements

great move

AMD

AMD

great move

move up the price curve

AMD

AMD

move up the price curve

focus more on the performance

AMD

AMD

focus more on the performance

more powerful

Vega 64

Vega 64

AMD

AMD

more powerful

the world 's most powerful

Radeon RX Vega

Radeon RX Vega

AMD

AMD

the world 's most powerful

more power hungry and more expensive

Vega 64

Vega 64

AMD

AMD

more power hungry and more expensive

reaches parity

Vega 64

Vega 64

AMD

AMD

reaches parity

trading some blows

NVIDIA

NVIDIA

trading some blows

trading some blows

AMD

AMD

trading some blows

inflated prices

NVIDIA

NVIDIA

inflated prices

trade blows

RX Vega 64

RX Vega 64

AMD

AMD

trade blows

higher power and not consistently

RX Vega 64

RX Vega 64

AMD

AMD

higher power and not consistently

save money

AMD

AMD

save money

enable more gamers

AMD

AMD

enable more gamers

free games and monitor discounts

AMD

AMD

free games and monitor discounts

help mitigate

AMD

AMD

help mitigate

popular

AMD

AMD

popular

translate to many sales

AMD

AMD

translate to many sales

higher volumes

AMD

AMD

higher volumes

brightest day

AMD

AMD

brightest day

capable of challenging

AMD

AMD

capable of challenging

compelling , powerful , enthusiast

AMD

AMD

compelling , powerful , enthusiast

stock-out issues

NVIDIA

NVIDIA

stock-out issues

pull the price lever

NVIDIA

NVIDIA

pull the price lever

sell as many cards as they can make

NVIDIA

NVIDIA

AMD

AMD

sell as many cards as they can make

good day

AMD

AMD

good day

move beyond

AMD

AMD

move beyond

Reviews Confirm With Radeon RX Vega , AMD Re-enters The Performance Desktop GPU Space
Many industry watchers including myself have been paying very close attention to AMD 's latest CPU and GPU products .
AMD was expected to give the competition a run for their money with Ryzen and Ryzen ThreadRipper desktop processors , and those expectations have been met in desktop CPUs .
Now we must wait and see in December how Ryzen will do in mobile APUs .
Vega-based graphics cards were also expected to bring more competition to the performance desktop GPU market .
AMD Radeon-based Polaris GPUs targeted the mainstream and entry-level market , priced $ 249 and below , and gave AMD 's RTG group a nice boost in unit market share , but the real margin dollars are in the high-end GPUs .
Therefore , Vega is important as it could help AMD increase revenues and margin dollars .
Earlier this year , AMD launched a very limited edition , low-volume high-price Vega-based , Radeon Instinct card for machine learning and just meeting their 1H 2017 launch promise .
So here we are in Q3 with new Radeon RX Vega 64 and RX Vega 56 GPUs each number indicates the amount of ROPs inside the GPU , and today we are starting to see a vast array of performance numbers from reviewers .
I did not get my Vega cards in time to do a complete review but will do that later .
However , before I dig too deeply into these performance numbers , let 's talk about market expectations and AMD 's promises for Vega .
Officially , AMD did not make many specific promises about Vega until the launch itself , but they did suggest that Vega would be `` very fast . ''
The reality is that when a company like AMD is expected to launch a new high-end GPU to compete at higher price points , they are going to be competitive with NVIDIA .
That means that the expectation is that AMD will either be competitive with NVIDIA on performance or they will be competitive with them on price , or typically , both .
That means that the market 's expectations were that AMD would compete with NVIDIA 's fastest card , the GTX 1080 , and maybe even its newer brother the GTX 1080 Ti which was announced in March this year .
At the company 's Financial Analyst Day , AMD showed some superb Instinct performance numbers , but backed off any absolute performance claims of the overall family and rather talked about overall improvements over previous generations .
I thought this was a great move as all AMD had to do to gain credibility and profitability were to move up the price curve .
At the consumer launch , there was very little head to head comparison and overall , and AMD seemed to focus more on the performance of Vega 56 over its more powerful brother Vega 64 .
AMD specifically stated that Radeon RX Vega is `` the world 's most powerful sub - $ 400 GPU . ''
This is likely because when you look at the reviews that have gone live today , Vega 64 is more power hungry and more expensive than Vega 56 and reaches parity with NVIDIA 's GTX 1080 , trading some blows .
As they should , countless reviews from PC Gamer , PCWorld , Anandtech , PC Perspective , Tom 's Hardware , and Hot Hardware have given AMD praise for the price and performance of the Vega 56 at $ 399 and how it 's very competitive in performance with NVIDIA 's popular GTX 1070 , especially with the card 's current inflated prices due to crypto currency mining .
Reviewers also mention that the RX Vega 64 does trade blows with the GTX 1080 which carries the same MSRP , but it does so at much higher power and not consistently .
AMD is also releasing a series of bundles to help new system builders save money and enable more gamers when they pair their RX Vega GPUs with Ryzen CPUs .
These bundles also include free games and monitor discounts , but one of their biggest purposes is to help mitigate the flow of miners buying GPUs and keeping them away from AMD 's loyal gamers .
While it remains to be seen how popular these bundles may be , they could drive some additional sales towards RX Vega 56 from customers who were already interested in building a Ryzen system .
Thankfully for AMD , a lot of the positive reviews for Radeon RX Vega 56 should still translate to many sales for the company as $ 399 cards still sell in much higher volumes than $ 499 and up .
If I can summarize AMD 's Radeon RX Vega launch from a few reviewer pull-quotes : `` In short , the Vega launch has the potential to be AMD 's brightest day , '' from Ryan Smith & Nate Oh at AnandTech .
`` The Red Team is fielding high-end graphics cards capable of challenging Nvidia 's enthusiast-class hardware , '' from Brad Chacos at PC World .
`` For their respective price points currently , AMD Radeon RX Vega 64 and Radeon RX Vega 56 are compelling , powerful , enthusiast gaming GPUs , '' from Dave Altavilla and Marco Chiappetta at Hot Hardware .
NVIDIA has a few hands they can play here , but given the stock-out issues driven by the recent Bitcoin mining frenzy , I do n't expect the company to pull the price lever .
I think in the short run , both AMD and NVIDIA can sell as many cards as they can make .
NVIDIA 's big move comes when they introduce 12nm , Volta-based GeForce consumer cards .
This will likely happen early 2018 so AMD and NVIDIA for the first time in a while will both participate in the $ 399 and $ 499 price points .
All in all , it was a good day for AMD Radeon as they showed with Vega , in consumer desktop graphics , they can move beyond the $ 249 price point to $ 399 and $ 499 .

Reviews Confirm With Radeon RX Vega , AMD Re-enters The Performance Desktop GPU Space Many industry watchers including myself have been paying very close attention to AMD ' s latest CPU and GPU products . AMD was expected to give the competition a run for their money with Ryzen and Ryzen ThreadRipper desktop processors , and those expectations have been met in desktop CPUs . Now we must wait and see in December how Ryzen will do in mobile APUs . Vega-based graphics cards were also expected to bring more competition to the performance desktop GPU market . AMD Radeon-based Polaris GPUs targeted the mainstream and entry-level market , priced $ 249 and below , and gave AMD ' s RTG group a nice boost in unit market share , but the real margin dollars are in the high-end GPUs . Therefore , Vega is important as it could help AMD increase revenues and margin dollars . Earlier this year , AMD launched a very limited edition , low-volume high-price Vega-based , Radeon Instinct card for machine learning and just meeting their 1H 2017 launch promise . So here we are in Q3 with new Radeon RX Vega 64 and RX Vega 56 GPUs each number indicates the amount of ROPs inside the GPU , and today we are starting to see a vast array of performance numbers from reviewers . I did not get my Vega cards in time to do a complete review but will do that later . However , before I dig too deeply into these performance numbers , let ' s talk about market expectations and AMD ' s promises for Vega . Officially , AMD did not make many specific promises about Vega until the launch itself , but they did suggest that Vega would be ` ` very fast . ' ' The reality is that when a company like AMD is expected to launch a new high-end GPU to compete at higher price points , they are going to be competitive with NVIDIA . That means that the expectation is that AMD will either be competitive with NVIDIA on performance or they will be competitive with them on price , or typically , both . That means that the market ' s expectations were that AMD would compete with NVIDIA ' s fastest card , the GTX 1080 , and maybe even its newer brother the GTX 1080 Ti which was announced in March this year . At the company ' s Financial Analyst Day , AMD showed some superb Instinct performance numbers , but backed off any absolute performance claims of the overall family and rather talked about overall improvements over previous generations . I thought this was a great move as all AMD had to do to gain credibility and profitability were to move up the price curve . At the consumer launch , there was very little head to head comparison and overall , and AMD seemed to focus more on the performance of Vega 56 over its more powerful brother Vega 64 . AMD specifically stated that Radeon RX Vega is ` ` the world ' s most powerful sub - $ 400 GPU . ' ' This is likely because when you look at the reviews that have gone live today , Vega 64 is more power hungry and more expensive than Vega 56 and reaches parity with NVIDIA ' s GTX 1080 , trading some blows . As they should , countless reviews from PC Gamer , PCWorld , Anandtech , PC Perspective , Tom ' s Hardware , and Hot Hardware have given AMD praise for the price and performance of the Vega 56 at $ 399 and how it ' s very competitive in performance with NVIDIA ' s popular GTX 1070 , especially with the card ' s current inflated prices due to crypto currency mining . Reviewers also mention that the RX Vega 64 does trade blows with the GTX 1080 which carries the same MSRP , but it does so at much higher power and not consistently . AMD is also releasing a series of bundles to help new system builders save money and enable more gamers when they pair their RX Vega GPUs with Ryzen CPUs . These bundles also include free games and monitor discounts , but one of their biggest purposes is to help mitigate the flow of miners buying GPUs and keeping them away from AMD ' s loyal gamers . While it remains to be seen how popular these bundles may be , they could drive some additional sales towards RX Vega 56 from customers who were already interested in building a Ryzen system . Thankfully for AMD , a lot of the positive reviews for Radeon RX Vega 56 should still translate to many sales for the company as $ 399 cards still sell in much higher volumes than $ 499 and up . If I can summarize AMD ' s Radeon RX Vega launch from a few reviewer pull-quotes : ` ` In short , the Vega launch has the potential to be AMD ' s brightest day , ' ' from Ryan Smith & Nate Oh at AnandTech . ` ` The Red Team is fielding high-end graphics cards capable of challenging Nvidia ' s enthusiast-class hardware , ' ' from Brad Chacos at PC World . ` ` For their respective price points currently , AMD Radeon RX Vega 64 and Radeon RX Vega 56 are compelling , powerful , enthusiast gaming GPUs , ' ' from Dave Altavilla and Marco Chiappetta at Hot Hardware . NVIDIA has a few hands they can play here , but given the stock-out issues driven by the recent Bitcoin mining frenzy , I do n't expect the company to pull the price lever . I think in the short run , both AMD and NVIDIA can sell as many cards as they can make . NVIDIA ' s big move comes when they introduce 12nm , Volta-based GeForce consumer cards . This will likely happen early 2018 so AMD and NVIDIA for the first time in a while will both participate in the $ 399 and $ 499 price points . All in all , it was a good day for AMD Radeon as they showed with Vega , in consumer desktop graphics , they can move beyond the $ 249 price point to $ 399 and $ 499 .


the past 20 years

the past 20 years

Amazon stock

Amazon stock

63,000 %

63,000 %

soared

soared

since going public 20 years ago

since going public 20 years ago

stock

stock

63,000 %

63,000 %

soar

soar

Amazon Web Services AWS

Amazon Web Services AWS

lead in the market

lead in the market

42 % year over year to $ 3.66 billion

42 % year over year to $ 3.66 billion

jumped

jumped

AWS

AWS

cloud infrastructure services

cloud infrastructure services

puts

puts

public cloud revenue

public cloud revenue

$ 236 billion

$ 236 billion

hit

hit

$ 14.99 per month

$ 14.99 per month

Prime members

Prime members

Amazon

Amazon

charging

charging

76 million

76 million

Prime Video subscribers

Prime Video subscribers

Amazon

Amazon

subscribers

subscribers

have

have

U.S.

U.S.

Netflix

Netflix

exceeds

exceeds

Amazon

Amazon

$ 5 billion

$ 5 billion

grow

grow

Done Growing

Amazon

Amazon

Done Growing

done

Amazon stock

Amazon stock

done

a penchant for disrupting industries

Amazon

Amazon

a penchant for disrupting industries

has worked wonders so far

Amazon

Amazon

has worked wonders so far

Amazon

Amazon

missed Amazon 's gravy train

investors

investors

missed Amazon 's gravy train

worry

investors

investors

worry

sustain the terrific growth

Amazon

Amazon

investors

investors

sustain the terrific growth

lead in the market

Microsoft

Microsoft

IBM

IBM

Alphabet

Alphabet

lead in the market

rapidly grown

AWS

AWS

rapidly grown

major moneymaker for the company

AWS

AWS

Amazon

Amazon

major moneymaker for the company

reaped big dividends

AWS

AWS

Amazon

Amazon

reaped big dividends

currently leads this space

AWS

AWS

Amazon

Amazon

currently leads this space

running a distant second

Microsoft 's Azure cloud

Microsoft 's Azure cloud

running a distant second

AWS

AWS

Amazon

Amazon

Amazon

Amazon

launch of the Amazon Chime service

Amazon

Amazon

launch of the Amazon Chime service

help it compete more effectively

Amazon

Amazon

help it compete more effectively

help it compete more effectively

Microsoft 's Skype tools

Microsoft 's Skype tools

help it compete more effectively

make a lot more money in this space

Amazon

Amazon

make a lot more money in this space

successfully defend its market share

Amazon

Amazon

successfully defend its market share

Amazon

Amazon

started testing

Amazon

Amazon

AmazonFresh

AmazonFresh

started testing

now testing this concept

Amazon

Amazon

AmazonFresh

AmazonFresh

now testing this concept

making a smart move

Amazon

Amazon

AmazonFresh

AmazonFresh

making a smart move

save a lot of time

Customers

Customers

save a lot of time

Amazon

Amazon

Prime Video

Prime Video

Netflix

Netflix

Hulu

Hulu

exceeds

Amazon

Amazon

exceeds

video subscriber growth

Amazon

Amazon

Prime Video subscribers

Prime Video subscribers

video subscriber growth

cheaper

Prime Video

Prime Video

cheaper

enhancing its appeal

Prime Video

Prime Video

enhancing its appeal

push up advertising dollars

Amazon

Amazon

Video

Video

push up advertising dollars

bring more subscribers into its fold

Amazon

Amazon

bring more subscribers into its fold

run out of steam

Amazon

Amazon

run out of steam

Amazon

Amazon

fast-growing industries

Amazon

Amazon

fast-growing industries

Amazon

Amazon

Amazon

Amazon

3 Reasons Amazon Is n't Done Growing Yet
Amazon stock has soared 63,000 % in the past 20 years , and this stock-watcher believes that it is not done yet .
Amazon has a penchant for disrupting industries .
For instance , it changed the way people bought and read books and is now working on futuristic delivery mechanisms such as self-driving trucks and drones .
Amazon 's strategy of pouring money aggressively into new ideas has worked wonders so far , helping the stock soar a whopping 63,000 % since going public 20 years ago as its top-line growth has taken off remarkably .
But investors who have missed Amazon 's gravy train so far should n't worry , as these three catalysts can help sustain the terrific growth .
Cloud growth Amazon 's cloud business came into being by accident , as the company initially wanted to build a service to help third-party retailers build their websites based on Amazon 's e-commerce infrastructure .
This idea gradually led to the formation of the Amazon Web Services AWS cloud infrastructure business in 2006 , giving it a tremendous lead in the market over rivals such as Microsoft , IBM , and Alphabet .
AWS has rapidly grown into a major moneymaker for the company .
The division 's revenue jumped 42 % year over year to $ 3.66 billion during the recently reported first quarter , thanks to the adoption of its platform by the likes of Snap , Dunkin' Brands , and many others .
That was about 10 % of total net sales .
More importantly , Amazon 's early move into cloud infrastructure services has reaped big dividends for the company , as AWS currently leads this space .
Market analyst firm Canalys puts AWS 's market share at 31 % in cloud infrastructure services , with Microsoft 's Azure cloud running a distant second .
In fact , AWS 's market share exceeds the combined strength of its three closest rivals , according to this data .
What 's more , the e-commerce giant is aggressively undertaking steps to defend its lead in this space by adding new features to its cloud services .
For instance , Amazon has now entered the software-as-a-service space with the launch of the Amazon Chime service in February .
This move should help it compete more effectively against Microsoft 's Skype tools that enable cloud-based communication .
Research and advisory firm Forrester expects public cloud revenue to hit a massive $ 236 billion in 2020 , so Amazon can make a lot more money in this space if it can successfully defend its market share .
Groceries
Amazon has started taking baby steps in the multibillion-dollar offline grocery market .
The company started testing the AmazonFresh concept in Seattle earlier this year , enabling customers to order items online then drive to an Amazon location for pick-up at a scheduled time , which can be as quick as 15 minutes after ordering .
The company is now testing this concept in Milwaukee as well , charging Amazon Prime members an additional $ 14.99 per month for the Fresh service .
The e-commerce giant is making a smart move by trying to sell groceries in this manner .
Customers can save a lot of time by pre-ordering items at home and paying online , while receiving fresh groceries at the appointed time .
Prime Video
Amazon 's Prime Video streaming service has reportedly racked up an impressive number of users within a short time , challenging established streaming companies such as Netflix and Hulu .
Amazon was estimated in 2016 to have 76 million Prime Video subscribers , which significantly exceeds Netflix 's 47 million U.S. subscribers .
The video subscriber growth is a result of the company 's strategy of bundling the service with the $ 99 annual fee for the Prime subscription , which also includes early access to deals and priority shipping .
The company also offers Prime Video as a stand-alone service for a monthly fee of $ 8.99 , making it cheaper than Netflix 's $ 9.99 plan while also enhancing its appeal among customers who do n't want the entire Prime package .
Video has also helped push up advertising dollars .
Amazon could bring more subscribers into its fold thanks to its latest move of offering live television through Prime Video , allowing customers to choose and pay for specific channels .
A Morgan Stanley research note has said Amazon 's advertising business could grow to $ 5 billion in 2018 .
The takeaway
Amazon is not going to run out of steam anytime soon as it pursues multibillion-dollar revenue opportunities in these fast-growing industries .
Investor should n't doubt the company 's ability to deliver more upside after fantastic gains over the past two decades .

3 Reasons Amazon Is n't Done Growing Yet Amazon stock has soared 63,000 % in the past 20 years , and this stock-watcher believes that it is not done yet . Amazon has a penchant for disrupting industries . For instance , it changed the way people bought and read books and is now working on futuristic delivery mechanisms such as self-driving trucks and drones . Amazon ' s strategy of pouring money aggressively into new ideas has worked wonders so far , helping the stock soar a whopping 63,000 % since going public 20 years ago as its top-line growth has taken off remarkably . But investors who have missed Amazon ' s gravy train so far should n't worry , as these three catalysts can help sustain the terrific growth . Cloud growth Amazon ' s cloud business came into being by accident , as the company initially wanted to build a service to help third-party retailers build their websites based on Amazon ' s e-commerce infrastructure . This idea gradually led to the formation of the Amazon Web Services AWS cloud infrastructure business in 2006 , giving it a tremendous lead in the market over rivals such as Microsoft , IBM , and Alphabet . AWS has rapidly grown into a major moneymaker for the company . The division ' s revenue jumped 42 % year over year to $ 3.66 billion during the recently reported first quarter , thanks to the adoption of its platform by the likes of Snap , Dunkin ' Brands , and many others . That was about 10 % of total net sales . More importantly , Amazon ' s early move into cloud infrastructure services has reaped big dividends for the company , as AWS currently leads this space . Market analyst firm Canalys puts AWS ' s market share at 31 % in cloud infrastructure services , with Microsoft ' s Azure cloud running a distant second . In fact , AWS ' s market share exceeds the combined strength of its three closest rivals , according to this data . What ' s more , the e-commerce giant is aggressively undertaking steps to defend its lead in this space by adding new features to its cloud services . For instance , Amazon has now entered the software-as-a-service space with the launch of the Amazon Chime service in February . This move should help it compete more effectively against Microsoft ' s Skype tools that enable cloud-based communication . Research and advisory firm Forrester expects public cloud revenue to hit a massive $ 236 billion in 2020 , so Amazon can make a lot more money in this space if it can successfully defend its market share . Groceries Amazon has started taking baby steps in the multibillion-dollar offline grocery market . The company started testing the AmazonFresh concept in Seattle earlier this year , enabling customers to order items online then drive to an Amazon location for pick-up at a scheduled time , which can be as quick as 15 minutes after ordering . The company is now testing this concept in Milwaukee as well , charging Amazon Prime members an additional $ 14.99 per month for the Fresh service . The e-commerce giant is making a smart move by trying to sell groceries in this manner . Customers can save a lot of time by pre-ordering items at home and paying online , while receiving fresh groceries at the appointed time . Prime Video Amazon ' s Prime Video streaming service has reportedly racked up an impressive number of users within a short time , challenging established streaming companies such as Netflix and Hulu . Amazon was estimated in 2016 to have 76 million Prime Video subscribers , which significantly exceeds Netflix ' s 47 million U.S . subscribers . The video subscriber growth is a result of the company ' s strategy of bundling the service with the $ 99 annual fee for the Prime subscription , which also includes early access to deals and priority shipping . The company also offers Prime Video as a stand-alone service for a monthly fee of $ 8.99 , making it cheaper than Netflix ' s $ 9.99 plan while also enhancing its appeal among customers who do n't want the entire Prime package . Video has also helped push up advertising dollars . Amazon could bring more subscribers into its fold thanks to its latest move of offering live television through Prime Video , allowing customers to choose and pay for specific channels . A Morgan Stanley research note has said Amazon ' s advertising business could grow to $ 5 billion in 2018 . The takeaway Amazon is not going to run out of steam anytime soon as it pursues multibillion-dollar revenue opportunities in these fast-growing industries . Investor should n't doubt the company ' s ability to deliver more upside after fantastic gains over the past two decades .


Boeing

Boeing

Contract

Contract

DARPA XS-1 Experimental Space Plane

DARPA XS-1 Experimental Space Plane

Boeing

Boeing

Build

Build

For nearly three years now

For nearly three years now

XS-1 Spaceplane

XS-1 Spaceplane

project

project

$ 1 billion a mission

$ 1 billion a mission

cost

cost

$ 5 million per flight

$ 5 million per flight

cost

cost

Vector

Vector

NASA

NASA

hired

hired

Vector

Vector

build

build

the spaceplane itself

the spaceplane itself

who

who

build

build

Boeing

Boeing

collaboration

collaboration

Northrop Grumman

Northrop Grumman

Sir Richard Branson 's Virgin Galactic

Sir Richard Branson 's Virgin Galactic

teaming up

teaming up

equally private XCOR Aerospace

equally private XCOR Aerospace

privately held Masten Space Systems

privately held Masten Space Systems

working with

working with

Boeing

Boeing

wins the prize

wins the prize

Blue Origin

Blue Origin

wins the prize

wins the prize

Boeing

Boeing

build

build

Boeing

Boeing

first

first

Boeing

Boeing

short-notice , low-cost access to space

short-notice , low-cost access to space

providing

providing

the XS-1 competition

the XS-1 competition

Boeing

Boeing

DARPA

DARPA

completed phase 1

completed phase 1

the company

the company

DARPA

DARPA

proceed through phases 2 and 3

proceed through phases 2 and 3

tapped

tapped

flight

flight

the company

the company

fabrication

fabrication

proceed through phases 2 and 3

proceed through phases 2 and 3

the Boeing team

the Boeing team

Blue Origin

Blue Origin

fallen off

fallen off

Blue Origin

Blue Origin

the Boeing team

the Boeing team

replaced

replaced

Aerojet Rocketdyne

Aerojet Rocketdyne

the Boeing team

the Boeing team

member

member

Aerojet Rocketdyne

Aerojet Rocketdyne

selected

selected

its spaceplane

its spaceplane

DARPA

DARPA

building

building

DARPA

DARPA

doing the work

doing the work

Aerojet Rocketdyne

Aerojet Rocketdyne

Boeing

Boeing

work

work

now

now

Boeing

Boeing

Aerojet Rocketdyne

Aerojet Rocketdyne

transforming

transforming

over the course of 10 days

over the course of 10 days

before the end of 2019

before the end of 2019

the Phantom Express

the Phantom Express

test-firings

test-firings

the aircraft

the aircraft

the companies

the companies

tests

tests

its contractors

its contractors

DARPA

DARPA

Phantom Express

Phantom Express

demonstrate

demonstrate

DARPA

DARPA

spaceflight

spaceflight

change the economics

change the economics

victory

Boeing

Boeing

victory

in the lurch

Blue Origin

Blue Origin

in the lurch

won

Boeing

Boeing

won

legacy Space Shuttle main engine SSME

Aerojet

Aerojet

DARPA

DARPA

legacy Space Shuttle main engine SSME

move into phase 2

Boeing

Boeing

Aerojet Rocketdyne

Aerojet Rocketdyne

move into phase 2

Boeing

Boeing

Aerojet Rocketdyne

Aerojet Rocketdyne

Boeing Wins Contract to Build DARPA XS-1 Experimental Space Plane
But hey !
What happened to Blue Origin ?
For nearly three years now , we 've been following the saga of the XS-1 Spaceplane -- the Defense Advanced Research Projects Agency 's DARPA project to build a new and improved , 21st-century space shuttle .
Designed to fly `` 10 times in 10 days , '' the unmanned XS-1 will rocket to the edge of space and then fire a different rocket to launch payloads into orbit -- never leaving the atmosphere itself , and never actually entering orbit .
Instead , after delivering its cargo the XS-1 will return to land on Earth like an airplane .
In contrast to the actual space shuttle , which famously cost about $ 1 billion a mission to fly , XS-1 aims to deliver up to 3,000 pounds of cargo to orbit for just $ 5 million per flight .
NASA has hired privately held Vector to build the second-stage `` rocket '' that will push payloads the last mile into orbit , using Vector 's internally developed Vector-R rocket for this purpose .
The question up till now , though , has been who would build the spaceplane itself .
Would it be : Boeing , in collaboration with Amazon.com CEO Jeff Bezos ' `` Blue Origin '' space company ?
Northrop Grumman , teaming up with Sir Richard Branson 's Virgin Galactic ?
Or privately held Masten Space Systems , working with equally private XCOR Aerospace ?
Now we know the answer : It 's Boeing ... and Aerojet Rocketdyne .
Boeing wins the prize -- but not Blue Origin
On Wednesday , May 24 , DARPA made its announcement : Boeing will `` build and fly an experimental vehicle for aircraft-like access to space . ''
Dubbed the Boeing Phantom Express , this will be the `` first of an entirely new class of hypersonic aircraft that would bolster national security by providing short-notice , low-cost access to space . ''
After Boeing successfully completed phase 1 of the XS-1 competition , DARPA has tapped the company to proceed through phases 2 and 3 as well -- fabrication and flight .
And yet , Boeing 's victory seems to have left Blue Origin in the lurch .
Somewhere between 2014 , when Boeing entered this competition , and this week , when Boeing won it , Blue Origin appears to have fallen off the Boeing team , to be replaced by Blue Origin 's rocket-building rival Aerojet Rocketdyne .
According to DARPA 's press release , `` the XS-1 technology demonstrator 's propulsion system is an Aerojet Rocketdyne AR-22 engine , a version of the legacy Space Shuttle main engine SSME . ''
In confirmation of this , Aerojet issued its own press release on Wednesday , stating that `` Aerojet Rocketdyne is a member of the Boeing team '' and that it has been `` selected to provide the main propulsion for the Boeing and the U.S. Defense Advanced Research Projects Agency DARPA reusable Experimental Spaceplane XS-1 . ''
So it 's official now : DARPA will proceed with building its spaceplane , with Boeing and Aerojet Rocketdyne doing the work .
So what happens now ?
What happens now According to DARPA , Boeing and Aerojet Rocketdyne now move into phase 2 of the project , transforming XS-1 from concept into aircraft .
This should be accomplished before the end of 2019 , and will include at least 10 test-firings of the Phantom Express ' engines over the course of 10 days .
This accomplished , the companies will proceed to phase 3 in 2020 , running between 12 and 15 flight tests to prove the aircraft can actually fly 10 times in 10 days .
Ultimately , DARPA will ask its contractors to demonstrate Phantom Express ' ability to hit flight speeds of Mach 10 , and launch a demonstration payload weighing between 900 and 3,000 pounds into low-earth orbit .
If they succeed in doing this , they 'll prove the ability to put a pound of payload in orbit for as little as $ 1,700 -- and change the economics of spaceflight forever .

Boeing Wins Contract to Build DARPA XS - 1 Experimental Space Plane But hey ! What happened to Blue Origin ? For nearly three years now , we ' ve been following the saga of the XS - 1 Spaceplane - - the Defense Advanced Research Projects Agency ' s DARPA project to build a new and improved , 21st-century space shuttle . Designed to fly ` ` 10 times in 10 days , ' ' the unmanned XS - 1 will rocket to the edge of space and then fire a different rocket to launch payloads into orbit - - never leaving the atmosphere itself , and never actually entering orbit . Instead , after delivering its cargo the XS - 1 will return to land on Earth like an airplane . In contrast to the actual space shuttle , which famously cost about $ 1 billion a mission to fly , XS - 1 aims to deliver up to 3,000 pounds of cargo to orbit for just $ 5 million per flight . NASA has hired privately held Vector to build the second-stage ` ` rocket ' ' that will push payloads the last mile into orbit , using Vector ' s internally developed Vector-R rocket for this purpose . The question up till now , though , has been who would build the spaceplane itself . Would it be : Boeing , in collaboration with Amazon.com CEO Jeff Bezos ' ` ` Blue Origin ' ' space company ? Northrop Grumman , teaming up with Sir Richard Branson ' s Virgin Galactic ? Or privately held Masten Space Systems , working with equally private XCOR Aerospace ? Now we know the answer : It ' s Boeing . . . and Aerojet Rocketdyne . Boeing wins the prize - - but not Blue Origin On Wednesday , May 24 , DARPA made its announcement : Boeing will ` ` build and fly an experimental vehicle for aircraft-like access to space . ' ' Dubbed the Boeing Phantom Express , this will be the ` ` first of an entirely new class of hypersonic aircraft that would bolster national security by providing short-notice , low-cost access to space . ' ' After Boeing successfully completed phase 1 of the XS - 1 competition , DARPA has tapped the company to proceed through phases 2 and 3 as well - - fabrication and flight . And yet , Boeing ' s victory seems to have left Blue Origin in the lurch . Somewhere between 2014 , when Boeing entered this competition , and this week , when Boeing won it , Blue Origin appears to have fallen off the Boeing team , to be replaced by Blue Origin ' s rocket-building rival Aerojet Rocketdyne . According to DARPA ' s press release , ` ` the XS - 1 technology demonstrator ' s propulsion system is an Aerojet Rocketdyne AR - 22 engine , a version of the legacy Space Shuttle main engine SSME . ' ' In confirmation of this , Aerojet issued its own press release on Wednesday , stating that ` ` Aerojet Rocketdyne is a member of the Boeing team ' ' and that it has been ` ` selected to provide the main propulsion for the Boeing and the U.S . Defense Advanced Research Projects Agency DARPA reusable Experimental Spaceplane XS - 1 . ' ' So it ' s official now : DARPA will proceed with building its spaceplane , with Boeing and Aerojet Rocketdyne doing the work . So what happens now ? What happens now According to DARPA , Boeing and Aerojet Rocketdyne now move into phase 2 of the project , transforming XS - 1 from concept into aircraft . This should be accomplished before the end of 2019 , and will include at least 10 test-firings of the Phantom Express ' engines over the course of 10 days . This accomplished , the companies will proceed to phase 3 in 2020 , running between 12 and 15 flight tests to prove the aircraft can actually fly 10 times in 10 days . Ultimately , DARPA will ask its contractors to demonstrate Phantom Express ' ability to hit flight speeds of Mach 10 , and launch a demonstration payload weighing between 900 and 3,000 pounds into low-earth orbit . If they succeed in doing this , they ' ll prove the ability to put a pound of payload in orbit for as little as $ 1,700 - - and change the economics of spaceflight forever .


Commercial banks ( XLF )

Commercial banks ( XLF )

higher numbers

higher numbers

Bank of America ( BAC )

Bank of America ( BAC )

$ 0.47

$ 0.47

earnings per share

earnings per share

$ 22.3 billion

$ 22.3 billion

The bank

The bank

revenue

revenue

7.6 %

7.6 %

J.P. Morgan ( JPM )

J.P. Morgan ( JPM )

$ 1.70

$ 1.70

EPS

EPS

$ 1.65

$ 1.65

J.P. Morgan ( JPM )

J.P. Morgan ( JPM )

6.5 %

6.5 %

EPS

EPS

$ 25.6 billion

$ 25.6 billion

JPM

JPM

revenues

revenues

after the 2007 financial crisis

after the 2007 financial crisis

Citigroup C

Citigroup C

banking giants

banking giants

slowest

slowest

after the 2007 financial crisis

after the 2007 financial crisis

Citigroup C

Citigroup C

banking giants

banking giants

lowest

lowest

The bank

The bank

$ 1.31

$ 1.31

EPS

EPS

$ 1.26

$ 1.26

The bank

The bank

EPS

EPS

1 %

1 %

The bank

The bank

revenue

revenue

0.3 %

0.3 %

The bank

The bank

revenue

revenue

costs

costs

Wells Fargo ( WFC )

Wells Fargo ( WFC )

$ 1.02

$ 1.02

EPS

EPS

Wells Fargo ( WFC )

Wells Fargo ( WFC )

$ 1.03

$ 1.03

EPS

EPS

$ 22.5 billion

$ 22.5 billion

The bank

The bank

revenue growth

revenue growth

the remainder of 2017

the remainder of 2017

the banking space

the banking space

banking space

banking space

offset by subdued growth

Commercial banks ( XLF )

Commercial banks ( XLF )

offset by subdued growth

rising net interest margins

Bank of America ( BAC )

Bank of America ( BAC )

rising net interest margins

loan book expansion

Bank of America ( BAC )

Bank of America ( BAC )

loan book expansion

credit card spending

Bank of America ( BAC )

Bank of America ( BAC )

credit card spending

trading activity

Bank of America ( BAC )

Bank of America ( BAC )

trading activity

a growth of

$ 22.3 billion

$ 22.3 billion

Bank of America ( BAC )

Bank of America ( BAC )

a growth of

a growth of

J.P. Morgan ( JPM )

J.P. Morgan ( JPM )

a growth of

a growth of

JPM

JPM

$ 25.6 billion

$ 25.6 billion

a growth of

strong quarter

JPM

JPM

strong quarter

JPM

JPM

higher advances

JPM

JPM

higher advances

trading activity

JPM

JPM

trading activity

weaker performance

Citigroup C

Citigroup C

weaker performance

lower advances

Citigroup C

Citigroup C

lower advances

subdued trading activity

Citigroup C

Citigroup C

subdued trading activity

loan book expansion

Wells Fargo ( WFC )

Wells Fargo ( WFC )

loan book expansion

NIM growth

Wells Fargo ( WFC )

Wells Fargo ( WFC )

NIM growth

higher trading activity

the banking space

the banking space

higher trading activity

subdued loan book expansion

the banking space

the banking space

subdued loan book expansion

marginal growth in NIMs

the banking space

the banking space

marginal growth in NIMs

interest rate hikes

the banking space

the banking space

interest rate hikes

What to Expect from BAC and Peers in 2017
Bank of America 's Future : Trump , Regulations , and the Fed
Commercial banks ( XLF ) are expected to post higher numbers in 2Q17 as well as in 2H17 based on higher rates , but these numbers will likely be offset by subdued growth in lending .
Specifically , Bank of America ( BAC ) is expected to post EPS earnings per share of $ 0.47 in 2Q17 and 3Q17 , fueled by rising net interest margins , loan book expansion , credit card spending , and trading activity .
The bank is expected to see revenue of $ 22.3 billion , which would be a growth of 7.2 % on a YoY year-over-year basis .
Major competitor J.P. Morgan ( JPM ) is expected to see EPS of $ 1.65 in 2Q17 and $ 1.70 in 3Q17 , reflecting a growth of 6.5 % and 7.6 % , respectively .
JPM is expected to see revenues of $ 25.6 billion , which would be a growth of 1.5 % in 2Q17 , mainly due to a strong quarter last year , similar levels of NIMs net interest margins , higher advances , and trading activity .
Citigroup C has seen the slowest growth and lowest valuations after the 2007 financial crisis among banking giants .
The bank is expected to post EPS of $ 1.26 and $ 1.31 in 2Q17 and 3Q17 , respectively .
The bank 's revenue is expected to expand at a growth of 1 % and 0.3 % in 2Q17 and 3Q17 , respectively .
This weaker performance reflects higher regulatory costs , lower advances , and subdued trading activity .
Wells Fargo ( WFC ) is expected to post EPS of $ 1.02 and $ 1.03 in 2Q17 and 3Q17 , respectively .
The bank is expected to post revenue growth of 1.6 % to $ 22.5 billion , driven by loan book expansion and NIM growth .
Overall , in the remainder of 2017 , the banking space is expected to see higher trading activity , subdued loan book expansion , and marginal growth in NIMs -- thanks to the Fed 's anticipated interest rate hikes .

What to Expect from BAC and Peers in 2017 Bank of America ' s Future : Trump , Regulations , and the Fed Commercial banks ( XLF ) are expected to post higher numbers in 2Q17 as well as in 2H17 based on higher rates , but these numbers will likely be offset by subdued growth in lending . Specifically , Bank of America ( BAC ) is expected to post EPS earnings per share of $ 0.47 in 2Q17 and 3Q17 , fueled by rising net interest margins , loan book expansion , credit card spending , and trading activity . The bank is expected to see revenue of $ 22.3 billion , which would be a growth of 7.2 % on a YoY year-over-year basis . Major competitor J.P . Morgan ( JPM ) is expected to see EPS of $ 1.65 in 2Q17 and $ 1.70 in 3Q17 , reflecting a growth of 6.5 % and 7.6 % , respectively . JPM is expected to see revenues of $ 25.6 billion , which would be a growth of 1.5 % in 2Q17 , mainly due to a strong quarter last year , similar levels of NIMs net interest margins , higher advances , and trading activity . Citigroup C has seen the slowest growth and lowest valuations after the 2007 financial crisis among banking giants . The bank is expected to post EPS of $ 1.26 and $ 1.31 in 2Q17 and 3Q17 , respectively . The bank ' s revenue is expected to expand at a growth of 1 % and 0.3 % in 2Q17 and 3Q17 , respectively . This weaker performance reflects higher regulatory costs , lower advances , and subdued trading activity . Wells Fargo ( WFC ) is expected to post EPS of $ 1.02 and $ 1.03 in 2Q17 and 3Q17 , respectively . The bank is expected to post revenue growth of 1.6 % to $ 22.5 billion , driven by loan book expansion and NIM growth . Overall , in the remainder of 2017 , the banking space is expected to see higher trading activity , subdued loan book expansion , and marginal growth in NIMs - - thanks to the Fed ' s anticipated interest rate hikes .


Juno Therapeutics

Juno Therapeutics

$ 46.4 Million

$ 46.4 Million

Spent

Spent

In March

In March

Juno Therapeutics

Juno Therapeutics

ending development

ending development

Juno

Juno

shelve

shelve

the biotech

the biotech

$ 46.4 million

$ 46.4 million

spent

spent

Juno

Juno

testing

testing

pediatric ALL

pediatric ALL

CAR-T

CAR-T

Juno

Juno

testing

testing

Biotech

Biotech

risky sector

risky sector

Juno

Juno

setback

setback

At ASCO

At ASCO

Juno

Juno

trial testing

trial testing

give investors confidence

give investors confidence

Failed Drug

Juno Therapeutics

Juno Therapeutics

Failed Drug

costly learning exercise

Juno Therapeutics

Juno Therapeutics

costly learning exercise

Juno Therapeutics

Juno Therapeutics

Juno Therapeutics

Juno Therapeutics

extremely strong efficacy data

Juno Therapeutics

Juno Therapeutics

extremely strong efficacy data

make JCAR015 safer

Juno Therapeutics

Juno Therapeutics

make JCAR015 safer

Juno

Juno

failed drug

Juno

Juno

failed drug

Juno

Juno

Novartis

Novartis

Kite Pharma

Kite Pharma

demise

Juno

Juno

demise

Juno

Juno

success

Novartis

Novartis

Kite Pharma

Kite Pharma

success

got unlucky

Juno

Juno

got unlucky

Juno

Juno

Juno

Juno

Juno

Juno

I Still Ca n't Believe Juno Therapeutics Spent $ 46.4 Million on This Failed Drug
A costly learning exercise .
In March , Juno Therapeutics announced that it was ending development of JCAR015 after five patients with acute lymphoblastic leukemia ( ALL ) died from cerebral edema -- brain swelling -- in its phase 2 clinical trial .
The lethal side effect made it unlikely the treatment could get approved , despite extremely strong efficacy data .
After a review of the data , the company said it thought there were protocol modifications and process improvements that would hopefully make JCAR015 safer , but those changes would require Juno to go back to phase 1 .
Since the biotech has other drug candidates to treat ALL , Juno made a decision with its partner Celgene that it would be best to shelve JCAR015 and focus on the other ALL therapies .
All told , the biotech spent $ 46.4 million on the failed drug , which could end up being a little higher depending on wrap-up costs .
The perils of an unproven technology  ( maybe )
JCAR015 was Juno 's lead CAR-T cell therapy , a relatively new type of cancer treatment in which patient 's T-cells are taken out of a patient 's body , treated so that they 're trained to attack the cancer cells expressing a specific protein , and then put back into the patient .
Kite Pharma and Novartis have gotten their CAR-T treatments past phase 3 without showing troubling side effects , albeit in a different type of blood cancer .
Juno is testing the target of JCAR015 , a protein called CD19 , with another CAR-T in patients with non-Hodgkin lymphoma NHL , so it probably is n't the target specifically .
And Juno is testing a CAR-T in pediatric ALL , where the company has n't seen a problem with cerebral edema .
In the end , the demise of JCAR015 was probably an unlucky combination of frail patients , the pre-treatment used to get patients ' bodies to accept the trained T-cells , and an overactive treatment .
Biotech is certainly a risky sector , but that risk is intensified when the underlying technology has n't been proven to work .
In this case , however , considering Kite Pharma 's and Novartis ' success , it might be that Juno just got unlucky more than anything else .
Righting the ship
At this point , JCAR015 is only a setback that does n't look like it 'll bring down the entire ship .
Juno has 11 treatments further back in the pipeline that use CAR-T or T Cell Receptor TCR , a related technology for targets that are inside the tumor cell .
Investors will get a look at how two of the early stage programs , JCAR017 and JCAR014 , are working at the American Society of Clinical Oncology ASCO meeting next month .
At ASCO , Juno will present phase 1 data for a trial testing JCAR017 in patients with NHL that have failed other treatments .
There will also be a presentation on the safety of JCAR014 , which will hopefully give investors confidence that JCAR015 's side effects are specific to that treatment and not an issue with the entire platform technology .

I Still Ca n't Believe Juno Therapeutics Spent $ 46.4 Million on This Failed Drug A costly learning exercise . In March , Juno Therapeutics announced that it was ending development of JCAR015 after five patients with acute lymphoblastic leukemia ( ALL ) died from cerebral edema - - brain swelling - - in its phase 2 clinical trial . The lethal side effect made it unlikely the treatment could get approved , despite extremely strong efficacy data . After a review of the data , the company said it thought there were protocol modifications and process improvements that would hopefully make JCAR015 safer , but those changes would require Juno to go back to phase 1 . Since the biotech has other drug candidates to treat ALL , Juno made a decision with its partner Celgene that it would be best to shelve JCAR015 and focus on the other ALL therapies . All told , the biotech spent $ 46.4 million on the failed drug , which could end up being a little higher depending on wrap-up costs . The perils of an unproven technology ( maybe ) JCAR015 was Juno ' s lead CAR-T cell therapy , a relatively new type of cancer treatment in which patient ' s T-cells are taken out of a patient ' s body , treated so that they ' re trained to attack the cancer cells expressing a specific protein , and then put back into the patient . Kite Pharma and Novartis have gotten their CAR-T treatments past phase 3 without showing troubling side effects , albeit in a different type of blood cancer . Juno is testing the target of JCAR015 , a protein called CD19 , with another CAR-T in patients with non-Hodgkin lymphoma NHL , so it probably is n't the target specifically . And Juno is testing a CAR-T in pediatric ALL , where the company has n't seen a problem with cerebral edema . In the end , the demise of JCAR015 was probably an unlucky combination of frail patients , the pre-treatment used to get patients ' bodies to accept the trained T-cells , and an overactive treatment . Biotech is certainly a risky sector , but that risk is intensified when the underlying technology has n't been proven to work . In this case , however , considering Kite Pharma ' s and Novartis ' success , it might be that Juno just got unlucky more than anything else . Righting the ship At this point , JCAR015 is only a setback that does n't look like it ' ll bring down the entire ship . Juno has 11 treatments further back in the pipeline that use CAR-T or T Cell Receptor TCR , a related technology for targets that are inside the tumor cell . Investors will get a look at how two of the early stage programs , JCAR017 and JCAR014 , are working at the American Society of Clinical Oncology ASCO meeting next month . At ASCO , Juno will present phase 1 data for a trial testing JCAR017 in patients with NHL that have failed other treatments . There will also be a presentation on the safety of JCAR014 , which will hopefully give investors confidence that JCAR015 ' s side effects are specific to that treatment and not an issue with the entire platform technology .


Chesapeake

Chesapeake

Merrill Lynch

Merrill Lynch

Downgrade

Downgrade

big brokerage firms

big brokerage firms

downgrades

downgrades

Chesapeake

Chesapeake

Merrill Lynch

Merrill Lynch

downgraded

downgraded

Merrill Lynch

Merrill Lynch

Chesapeake

Chesapeake

Underperform

Underperform

Chesapeake

Chesapeake

price objective to $ 8

price objective to $ 8

The firm

The firm

lowered

lowered

Underperform

Underperform

more than a small fraction under 1 %

more than a small fraction under 1 %

the stock

the stock

down

down

$ 5.75

$ 5.75

the stock

the stock

closing price

closing price

Thursday

Thursday

of Chesapeake

of Chesapeake

downgrade

downgrade

oil and gas sector

oil and gas sector

rotation call

rotation call

targets

targets

ratings

ratings

many companies

many companies

oil

oil

recovery

recovery

Analyst Doug Leggate and his team

Analyst Doug Leggate and his team

Chesapeake

Chesapeake

rate

rate

Chesapeake

Chesapeake

oil

oil

recovery

recovery

the company

the company

reducing

reducing

the company

the company

improving

improving

of $ 8

of $ 8

Our

Our

objective

objective

DACF

DACF

core NAV

core NAV

after Chesapeake 's earnings recently

after Chesapeake 's earnings recently

Chesapeake

Chesapeake

Merrill Lynch

Merrill Lynch

maintained

maintained

recently

recently

Chesapeake

Chesapeake

earnings

earnings

for West Texas Intermediate

for West Texas Intermediate

$ 67.59

$ 67.59

$ 3.50

$ 3.50

for Henry Hub

for Henry Hub

Merrill Lynch

Merrill Lynch

assumptions

assumptions

price target

price target

Chesapeake

Chesapeake

retains

retains

lowering

lowering

renegotiating

renegotiating

improving

improving

long term

long term

oil and gas price

oil and gas price

weakness

weakness

Chesapeake

Chesapeake

leverage

leverage

of approximately $ 9.3 billion

of approximately $ 9.3 billion

to $ 9.7 billion

to $ 9.7 billion

debt

debt

on April 28th

on April 28th

paid $ 441 million

paid $ 441 million

Chesapeake

Chesapeake

judgment

judgment

Chesapeake

Chesapeake

litigation

litigation

Chesapeake

Chesapeake

flexibility

flexibility

volatility

volatility

at $ 5.74

at $ 5.74

Chesapeake shares

Chesapeake shares

trading down just one cent

trading down just one cent

shares

shares

a 52-week

a 52-week

of $ 3.56 to $ 8.29

of $ 3.56 to $ 8.29

Chesapeake

Chesapeake

trading range

trading range

analyst

analyst

Chesapeake

Chesapeake

of $ 7.08

of $ 7.08

target price

target price

$ 8

$ 8

objective

objective

downgraded

downgraded

create a stir

investors

investors

Chesapeake

Chesapeake

create a stir

appear to be the case

Chesapeake Energy Corp

Chesapeake Energy Corp

appear to be the case

too much upside

Chesapeake

Chesapeake

too much upside

upside

Chesapeake

Chesapeake

upside

unfavorable impact

unfavorable impact

slower than expected

oil

oil

slower than expected

little upside

many companies

many companies

little upside

Underperform

Chesapeake

Chesapeake

Underperform

unfavorable impact

Chesapeake

Chesapeake

unfavorable impact

made significant strides

Chesapeake

Chesapeake

made significant strides

highly leveraged

Chesapeake

Chesapeake

highly leveraged

reducing financial complexity

Chesapeake

Chesapeake

reducing financial complexity

ticked higher

ticked higher

increased focused on the balance sheet

Chesapeake

Chesapeake

increased focused on the balance sheet

be more difficult

Chesapeake

Chesapeake

be more difficult

an improving operating backlog

Chesapeake

Chesapeake

an improving operating backlog

meaningful asset sales

Chesapeake

Chesapeake

meaningful asset sales

upside at our base case is limited

Chesapeake

Chesapeake

upside at our base case is limited

had much more concern

Chesapeake

Chesapeake

had much more concern

Was the Merrill Lynch Downgrade of Chesapeake Justified ?
When big brokerage firms make big analyst downgrades , it can create a stir for investors .
That does not appear to be the case in Chesapeake Energy Corp. ( CHK ) .
In a sector value rotation , Merrill Lynch downgraded Chesapeake to Underperform from Neutral .
The firm also lowered Chesapeake 's price objective to $ 8 from $ 10 .
It appears by the trading reaction that investors think the call is late , misguided or still just implies too much upside to be as negative as the Underperform rating might sound .
Otherwise , the stock might be down more than a small fraction under 1 % , and the call still implies some upside from the $ 5.75 prior closing price .
Thursday 's downgrade of Chesapeake was actually in a large oil and gas sector rotation call that included many names , such as Exxon Mobil , Cabot , ConocoPhillips and Noble .
Many targets were changed , and some key ratings were changed .
One issue to consider is that the changes were from the unfavorable impact of a slower than expected oil recovery , with many companies seeming to have very little upside at current strip prices .
Analyst Doug Leggate and his team said of Chesapeake :
We rate Chesapeake as Underperform due to the unfavorable impact of a slower oil recovery .
While the company has made significant strides in reducing costs and improving its balance sheet , the company is highly leveraged at weak oil and gas prices .
... Our price objective of $ 8 is based on a five-year outlook which assumes a mid-cycle 5.5 times its DACF multiple and a commodity deck of $ 68.00 WTI / $ 3.25 HH .
The multiple is based on a finite timeline to delivery , which is supported by core NAV .
When Merrill Lynch maintained a Neutral rating after Chesapeake 's earnings recently , its price deck assumptions were $ 67.59 for West Texas Intermediate and $ 3.50 for Henry Hub .
Despite this still implying more than 40 % to the lowered price target , Leggate 's report said :
Chesapeake retains little upside at current strip prices .
While we continue to believe that under CEO Doug Lawler significant strides have been made as far as lowering costs , renegotiating legacy takeaway agreements , reducing financial complexity and improving the balance sheet , if long term oil and gas price weakness persist , the company has still too much leverage .
With net debt of approximately $ 9.3 billion , which may have recently ticked higher to $ 9.7 billion given it paid $ 441 million on April 28th to satisfy a judgment related to its 2019 notes litigation .
With increased focused on the balance sheet , we believe that it may be more difficult for it to have the flexibility to fully exploit an improving operating backlog without meaningful asset sales ... we believe outsize volatility fits less well with a more conservative near term sector view while versus multiple other names , upside at our base case is limited .
Chesapeake shares were last seen trading down just one cent at $ 5.74 halfway through Thursday 's trading session .
Chesapeake has a 52-week trading range of $ 3.56 to $ 8.29 , and it has a consensus analyst target price of $ 7.08 .
Suddenly , an $ 8 price objective does n't sound so bad , even if this downgraded might have had much more concern if you just looked at the analyst summary without considering the explanations inside that call .

Was the Merrill Lynch Downgrade of Chesapeake Justified ? When big brokerage firms make big analyst downgrades , it can create a stir for investors . That does not appear to be the case in Chesapeake Energy Corp . ( CHK ) . In a sector value rotation , Merrill Lynch downgraded Chesapeake to Underperform from Neutral . The firm also lowered Chesapeake ' s price objective to $ 8 from $ 10 . It appears by the trading reaction that investors think the call is late , misguided or still just implies too much upside to be as negative as the Underperform rating might sound . Otherwise , the stock might be down more than a small fraction under 1 % , and the call still implies some upside from the $ 5.75 prior closing price . Thursday ' s downgrade of Chesapeake was actually in a large oil and gas sector rotation call that included many names , such as Exxon Mobil , Cabot , ConocoPhillips and Noble . Many targets were changed , and some key ratings were changed . One issue to consider is that the changes were from the unfavorable impact of a slower than expected oil recovery , with many companies seeming to have very little upside at current strip prices . Analyst Doug Leggate and his team said of Chesapeake : We rate Chesapeake as Underperform due to the unfavorable impact of a slower oil recovery . While the company has made significant strides in reducing costs and improving its balance sheet , the company is highly leveraged at weak oil and gas prices . . . . Our price objective of $ 8 is based on a five-year outlook which assumes a mid-cycle 5.5 times its DACF multiple and a commodity deck of $ 68.00 WTI / $ 3.25 HH . The multiple is based on a finite timeline to delivery , which is supported by core NAV . When Merrill Lynch maintained a Neutral rating after Chesapeake ' s earnings recently , its price deck assumptions were $ 67.59 for West Texas Intermediate and $ 3.50 for Henry Hub . Despite this still implying more than 40 % to the lowered price target , Leggate ' s report said : Chesapeake retains little upside at current strip prices . While we continue to believe that under CEO Doug Lawler significant strides have been made as far as lowering costs , renegotiating legacy takeaway agreements , reducing financial complexity and improving the balance sheet , if long term oil and gas price weakness persist , the company has still too much leverage . With net debt of approximately $ 9.3 billion , which may have recently ticked higher to $ 9.7 billion given it paid $ 441 million on April 28th to satisfy a judgment related to its 2019 notes litigation . With increased focused on the balance sheet , we believe that it may be more difficult for it to have the flexibility to fully exploit an improving operating backlog without meaningful asset sales . . . we believe outsize volatility fits less well with a more conservative near term sector view while versus multiple other names , upside at our base case is limited . Chesapeake shares were last seen trading down just one cent at $ 5.74 halfway through Thursday ' s trading session . Chesapeake has a 52 - week trading range of $ 3.56 to $ 8.29 , and it has a consensus analyst target price of $ 7.08 . Suddenly , an $ 8 price objective does n't sound so bad , even if this downgraded might have had much more concern if you just looked at the analyst summary without considering the explanations inside that call .